Table 2.
The correlation between the pCR and different clinical-pathological features
| Variable | n (%) | pCR (%) | χ2-value | P value |
|---|---|---|---|---|
| Age (yr) | 0.402 | 0.526 | ||
| ≤35 | 20 (22.0) | 8 (40.0) | ||
| >35 | 71 (78.0) | 23 (32.4) | ||
| Menstrual status | 0.016 | 0.898 | ||
| Pre-menopause | 39 (42.9) | 13 (33.3) | ||
| Post-menopause | 52 (57.1) | 18 (34.6) | ||
| Tumor size before NAC | 4.390 | 0.036 | ||
| cT1-cT2 | 57 (62.6) | 24 (42.1) | ||
| cT3-cT4 | 34 (37.4) | 7 (20.6) | ||
| Histological grade | 3.436 | 0.061 | ||
| 1/2 | 35 (38.5) | 17 (37.1) | ||
| 3 | 56 (61.5) | 14 (23.2) | ||
| Histological type | 0.073 | 0.786 | ||
| Ductal | 78 (85.7) | 27 (34.6) | ||
| Others | 13 (14.3) | 4 (30.8) | ||
| LVI | 4.919 | 0.027 | ||
| Negative | 53 (58.2) | 23 (43.4) | ||
| Positive | 38 (41.8) | 8 (21.1) | ||
| Nodal status before NAC | 4.793 | 0.029 | ||
| Negative | 33 (36.3) | 17 (51.5) | ||
| Positive | 58 (63.7) | 15 (24.1) | ||
| Ki67 | 2.752 | 0.097 | ||
| <14 | 28 (30.8) | 13 (46.4) | ||
| ≥14 | 63 (69.2) | 18 (28.6) | ||
| CD163 expression | 5.010 | 0.025 | ||
| High | 35 (38.5) | 7 (20.0) | ||
| Low | 56 (61.5) | 24 (42.9) | ||
| NAC regimen | 0.268 | 0.875 | ||
| EC-T | 19 (20.9) | 7 (31.6) | ||
| TEC | 59 (64.8) | 19 (25.4) | ||
| PE | 13 (14.3) | 5 (30.8) |
NAC: neoadjuvant chemotherapy; LVI: lymphovascular invasion; EC-T: epirubicin, cyclophosphamide, docetaxel; TEC: docetaxel, cyclophosphamide, epirubicin PE: paclitaxel, epirubicin; OR:Odds ratio; pCR: pathological complete response; BCS: breast-conserving surgery; CI: Confidence interval.